CompletedNCT02232529
Safety and Drug Levels of MIN-101 in Healthy Volunteers
About this title
Read the official source — NCT02232529Medication studyAges 18–50United KingdomSchizophrenia
Understand this study
Who was this study for?
Listed age limits: 18 years to 50 years.
- Listed locations
- Ruddington, NottinghamSee all locations and recruitment
- Study phase
- Phase 1Usually an early study focused on safety, tolerability, dosage, and side effects.
Study information
Study start dateSeptember 2014
- Recruitment status
- Completed
- Enrollment listed in the registry
- 32
- Sponsor
- Minerva Neurosciences
- Sponsor type
- Unknown or unclear
- Study type
- Drug
- Intervention type
- Drug
- Study phase
- Phase 1Usually an early study focused on safety, tolerability, dosage, and side effects.
- Locations
- United Kingdom
- Age range
- From 18 Years to 50 Years
- Official registry ID
- NCT02232529
- Official title
Show the full official title
A Two-Part Study Designed to Evaluate the Pharmacokinetic Profile of MIN-101 and Its Main Metabolites Following Single and Multiple Dose Modified Release Prototype Formulation Administration in Healthy Cytochrome P450 2D6 Extensive Metabolizer Male and Female Subjects, and to Evaluate the Relationship Between the Pharmacokinetic Profile of MIN-101 and Its Main Metabolites and Cardiovascular Parameters.
Looking for a study you can join?
Explore recruiting studiesRecruitment & locations
CompletedThis badge reflects the study status reported by the registry. Check the registry for the latest information.
Ruddington, Nottingham
Interested in joining this study?
Questions about this study
Who is behind this study?
The study sponsor is Minerva Neurosciences.
Did this study involve medication?
Yes. The study involved medication, including MIN-101 and Placebo.
Who was this study for?
Listed age limits: 18 years to 50 years.
